Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

New SARS-CoV-2 Omicron Variant with Spike Protein Mutation Y451H, Kilifi, Kenya, March-May 2023.

Mwanga MJ. et al, (2023), Emerg Infect Dis, 29, 2376 - 2379

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults.

Green C. et al, (2023), Clin Exp Immunol, 211, 269 - 279

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.

Mazur NI. et al, (2023), Lancet Infect Dis, 23, e2 - e21

Development of a controlled human infection model to study respiratory syncytial virus infection in older adults

Sande CJ., (2022), The Lancet Healthy Longevity, 3, e370 - e371

Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries.

Carbonell-Estrany X. et al, (2022), Front Pediatr, 10

Enrichment approach for unbiased sequencing of respiratory syncytial virus directly from clinical samples.

Waweru JW. et al, (2021), Wellcome open research, 6

Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU).

Jefferies K. et al, (2020), J Infect Dis, 222, S658 - S665

Include forthcoming?